Find Aviptadil Acetate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Guinea pig vip, Guinea pig vip octacosapeptide, Vip, human, porcine, rat vip (28 amino acids), 96886-24-7, Akos034834067
Molecular Formula
C147H239N43O42S2
Molecular Weight
3344.9  g/mol
InChI Key
UGKBLTCXYMBLJU-UHFFFAOYSA-N

Aviptadil Acetate
1 2D Structure

Aviptadil Acetate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[1-[[6-amino-1-[[5-amino-1-[[1-[[1-[[1-[[6-amino-1-[[6-amino-1-[[1-[[1-[[4-amino-1-[[1-[[1-[[1-[(1,4-diamino-1,4-dioxobutan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[2-[[2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-oxobutanoic acid
2.1.2 InChI
InChI=1S/C147H239N43O42S2/c1-71(2)55-97(175-120(207)77(12)165-130(217)105(65-112(201)202)181-140(227)107(68-191)185-121(208)87(151)62-84-67-160-70-163-84)133(220)179-102(59-81-29-19-18-20-30-81)137(224)189-117(80(15)195)145(232)184-106(66-113(203)204)139(226)190-116(79(14)194)144(231)183-103(61-83-38-42-86(197)43-39-83)138(225)188-115(78(13)193)143(230)173-92(35-28-52-162-147(158)159)127(214)176-98(56-72(3)4)131(218)170-91(34-27-51-161-146(156)157)125(212)167-89(32-22-25-49-149)124(211)171-93(44-45-109(152)198)128(215)172-94(46-53-233-16)122(209)164-76(11)119(206)166-95(47-54-234-17)129(216)169-88(31-21-24-48-148)123(210)168-90(33-23-26-50-150)126(213)178-101(60-82-36-40-85(196)41-37-82)135(222)177-99(57-73(5)6)134(221)180-104(64-111(154)200)136(223)186-108(69-192)141(228)187-114(75(9)10)142(229)182-100(58-74(7)8)132(219)174-96(118(155)205)63-110(153)199/h18-20,29-30,36-43,67,70-80,87-108,114-117,191-197H,21-28,31-35,44-66,68-69,148-151H2,1-17H3,(H2,152,198)(H2,153,199)(H2,154,200)(H2,155,205)(H,160,163)(H,164,209)(H,165,217)(H,166,206)(H,167,212)(H,168,210)(H,169,216)(H,170,218)(H,171,211)(H,172,215)(H,173,230)(H,174,219)(H,175,207)(H,176,214)(H,177,222)(H,178,213)(H,179,220)(H,180,221)(H,181,227)(H,182,229)(H,183,231)(H,184,232)(H,185,208)(H,186,223)(H,187,228)(H,188,225)(H,189,224)(H,190,226)(H,201,202)(H,203,204)(H4,156,157,161)(H4,158,159,162)
2.1.3 InChI Key
UGKBLTCXYMBLJU-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)CC(C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)O)C(=O)NC(CC(=O)O)C(=O)NC(C(C)O)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(C(C)O)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)NC(CCC(=O)N)C(=O)NC(CCSC)C(=O)NC(C)C(=O)NC(CCSC)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC3=CC=C(C=C3)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(C(C)C)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)N)C(=O)N)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC4=CNC=N4)N
2.2 Synonyms
2.2.1 MeSH Synonyms

1. Aviptadil

2. Invicorp

3. Porcine Vasoactive Intestinal Octacosapeptide

4. Rlf-100

5. Zyesami

2.2.2 Depositor-Supplied Synonyms

1. Guinea Pig Vip

2. Guinea Pig Vip Octacosapeptide

3. Vip, Human, Porcine, Rat Vip (28 Amino Acids)

4. 96886-24-7

5. Akos034834067

2.3 Create Date
2007-07-04
3 Chemical and Physical Properties
Molecular Weight 3344.9 g/mol
Molecular Formula C147H239N43O42S2
XLogP3-13.7
Hydrogen Bond Donor Count51
Hydrogen Bond Acceptor Count51
Rotatable Bond Count116
Exact Mass3343.7362760 g/mol
Monoisotopic Mass3342.7329212 g/mol
Topological Polar Surface Area1480 Ų
Heavy Atom Count234
Formal Charge0
Complexity7510
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count31
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Drugs in Development

read-more
read-more

Details:

Aviptadil is a synthetic form of vasoactive intestinal peptide (VIP) that, when administered, results in rapid clinical recovery in patients with severe SARS-COV-2 infection. Biophore has successfully developed aviptadil and is backward integrated with in-house API.


Lead Product(s): Aviptadil Acetate

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 11, 2021

Biophore

01

Lead Product(s) : Aviptadil Acetate

Therapeutic Area : Pulmonary/Respiratory Diseases

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Aviptadil is a synthetic form of vasoactive intestinal peptide (VIP) that, when administered, results in rapid clinical recovery in patients with severe SARS-COV-2 infection. Biophore has successfully developed aviptadil and is backward integrated with i...

Brand Name : Undisclosed

Molecule Type : Peptide

Upfront Cash : Not Applicable

June 11, 2021

Biophore

Details:

Biophore has developed Aviptadil and is backward integrated with in-house API. The company has also informed that it will be commencing commercial production immediately after the approval is received.


Lead Product(s): Aviptadil Acetate

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 11, 2021

Biophore

02

Lead Product(s) : Aviptadil Acetate

Therapeutic Area : Infections and Infectious Diseases

Highest Development Status : Phase III

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Biophore has developed Aviptadil and is backward integrated with in-house API. The company has also informed that it will be commencing commercial production immediately after the approval is received.

Brand Name : Undisclosed

Molecule Type : Peptide

Upfront Cash : Not Applicable

June 11, 2021

Biophore

Details:

RLF-100® (aviptadil acetate) restores barrier function at the endothelial/alveolar interface and thereby protects the lung and other organs from failure. It is under development for the potential treatment of acute and chronic lung disease.


Lead Product(s): Aviptadil Acetate

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RLF-100

Study Phase: Phase II/ Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 17, 2023

blank

03

Relief Therapeutics

Switzerland
arrow
American Pharma Summit
Not Confirmed

Relief Therapeutics

Switzerland
arrow
American Pharma Summit
Not Confirmed

Details : RLF-100® (aviptadil acetate) restores barrier function at the endothelial/alveolar interface and thereby protects the lung and other organs from failure. It is under development for the potential treatment of acute and chronic lung disease.

Brand Name : RLF-100

Molecule Type : Peptide

Upfront Cash : Not Applicable

April 17, 2023

blank

Details:

Zyesami (aviptadil acetate) is an inhaled formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP) in development for the treatment of patients with critical COVID-19 respiratory failure.


Lead Product(s): Aviptadil Acetate

Therapeutic Area: Infections and Infectious Diseases Brand Name: Zyesami

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Relief Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement December 19, 2022

blank

04

American Pharma Summit
Not Confirmed
American Pharma Summit
Not Confirmed

Details : Zyesami (aviptadil acetate) is an inhaled formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP) in development for the treatment of patients with critical COVID-19 respiratory failure.

Brand Name : Zyesami

Molecule Type : Peptide

Upfront Cash : Undisclosed

December 19, 2022

blank

Details:

APR-TD011 has potential for the treatment of wounds in epidermolysis bullosa ("EB"), a group of rare, genetic, life-threatening connective tissue disorders characterized by fragile skin and mucous membrane with severe blistering throughout the body.


Lead Product(s): Aviptadil Acetate

Therapeutic Area: Infections and Infectious Diseases Brand Name: Zyesami

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Relief Therapeutics

Deal Size: $30.0 million Upfront Cash: Undisclosed

Deal Type: Agreement November 14, 2022

blank

05

American Pharma Summit
Not Confirmed
American Pharma Summit
Not Confirmed

Details : APR-TD011 has potential for the treatment of wounds in epidermolysis bullosa ("EB"), a group of rare, genetic, life-threatening connective tissue disorders characterized by fragile skin and mucous membrane with severe blistering throughout the body.

Brand Name : Zyesami

Molecule Type : Peptide

Upfront Cash : Undisclosed

November 14, 2022

blank

Details:

RLF-100® (aviptadil) is a synthetic form of Vasoactive Intestinal Peptide (“VIP”) consisting of 28 amino acids. The reported data demonstrated high purity levels at six months at all temperatures tested, including at refrigerated and room temperature environments.


Lead Product(s): Aviptadil Acetate

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RLF-100

Study Phase: Phase II/ Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 07, 2022

blank

06

Relief Therapeutics

Switzerland
arrow
American Pharma Summit
Not Confirmed

Relief Therapeutics

Switzerland
arrow
American Pharma Summit
Not Confirmed

Details : RLF-100® (aviptadil) is a synthetic form of Vasoactive Intestinal Peptide (“VIP”) consisting of 28 amino acids. The reported data demonstrated high purity levels at six months at all temperatures tested, including at refrigerated and room temperatur...

Brand Name : RLF-100

Molecule Type : Peptide

Upfront Cash : Not Applicable

November 07, 2022

blank

Details:

RLF-100® (aviptadil) is a synthetic form of Vasoactive Intestinal Peptide ("VIP") consisting of 28 amino acids, is under development for certain acute and chronic lung diseases, including pulmonary sarcoidosis.


Lead Product(s): Aviptadil Acetate

Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: RLF-100

Study Phase: Phase II/ Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 03, 2022

blank

07

Relief Therapeutics

Switzerland
arrow
American Pharma Summit
Not Confirmed

Relief Therapeutics

Switzerland
arrow
American Pharma Summit
Not Confirmed

Details : RLF-100® (aviptadil) is a synthetic form of Vasoactive Intestinal Peptide ("VIP") consisting of 28 amino acids, is under development for certain acute and chronic lung diseases, including pulmonary sarcoidosis.

Brand Name : RLF-100

Molecule Type : Peptide

Upfront Cash : Not Applicable

August 03, 2022

blank

Details:

Zyesami (aviptadil acetate) is an inhaled formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP) in development for the treatment of patients with critical COVID-19 respiratory failure.


Lead Product(s): Aviptadil Acetate

Therapeutic Area: Infections and Infectious Diseases Brand Name: Zyesami

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 01, 2022

blank

08

American Pharma Summit
Not Confirmed
American Pharma Summit
Not Confirmed

Details : Zyesami (aviptadil acetate) is an inhaled formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP) in development for the treatment of patients with critical COVID-19 respiratory failure.

Brand Name : Zyesami

Molecule Type : Peptide

Upfront Cash : Not Applicable

July 01, 2022

blank

Details:

ZYESAMI (aviptadil), is an inhaled formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP) in development for the treatment of patients with critical COVID-19 respiratory failure.


Lead Product(s): Aviptadil Acetate

Therapeutic Area: Psychiatry/Psychology Brand Name: Zyesami

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 10, 2022

blank

09

American Pharma Summit
Not Confirmed
American Pharma Summit
Not Confirmed

Details : ZYESAMI (aviptadil), is an inhaled formulation of synthetic human Vasoactive Intestinal Polypeptide (VIP) in development for the treatment of patients with critical COVID-19 respiratory failure.

Brand Name : Zyesami

Molecule Type : Peptide

Upfront Cash : Not Applicable

June 10, 2022

blank

Details:

The primary endpoint (90 day 6-category ordinal score) was not supportive (OR 1.10; 0.79 – 1.54; p=0.56), and 90-day mortality secondary endpoint was also not supportive with 37% mortality in Zyesami (aviptadil) group vs 36% in the placebo group; HR 1.04 (0.77-1.41); p=0.79.


Lead Product(s): Aviptadil Acetate,Remdesivir

Therapeutic Area: Infections and Infectious Diseases Brand Name: Zyesami

Study Phase: Phase IIIProduct Type: Peptide

Sponsor: National Institutes of Health

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 25, 2022

blank

10

American Pharma Summit
Not Confirmed
American Pharma Summit
Not Confirmed

Details : The primary endpoint (90 day 6-category ordinal score) was not supportive (OR 1.10; 0.79 – 1.54; p=0.56), and 90-day mortality secondary endpoint was also not supportive with 37% mortality in Zyesami (aviptadil) group vs 36% in the placebo group; HR 1....

Brand Name : Zyesami

Molecule Type : Peptide

Upfront Cash : Not Applicable

May 25, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty